INSM

Insmed, Inc.

$122.88

+1.42%
Nov 16, 2026
Bobby Quantitative Model
Insmed, Inc. is a commercial-stage biopharmaceutical company organized around three therapeutic areas — Respiratory, Immunology and Inflammation, and Neuro and Other Rare — with two marketed products, Arikayce (amikacin liposome inhalation suspension) and Brinsupri (brensocatib), plus a clinical pipeline spanning TPIP, INS1148, INS1201 and pre-clinical platforms in gene therapy, AI-driven protein engineering and RNA end-joining. Insmed has evolved from a single-asset rare-disease story into a multi-product respiratory and inflammation platform, with brensocatib's launch representing one of the most closely watched new-product ramps in orphan lung disease and positioning the company as a potential category leader in bronchiectasis. The investor narrative is now dominated by the brensocatib commercialization curve and operating leverage: revenue has scaled dramatically year-over-year while losses narrowed sharply through 2026, and the FDA's acceptance of a priority-review filing to expand Arikayce's label (September 2026) added a second near-term catalyst. Debate centers on whether the steep re-acceleration in quarterly revenue is durable, whether R&D and SG&A spend can be absorbed without further dilution, and why the stock remains deeply discounted versus its 52-week high despite a strong fundamental inflection.

People also watch

Vertex Pharmaceuticals

Vertex Pharmaceuticals

VRTX

Analysis
Regeneron Pharmaceuticals

Regeneron Pharmaceuticals

REGN

Analysis
Moderna

Moderna

MRNA

Analysis
BeOne Medicines Ltd. American Depositary Shares

BeOne Medicines Ltd. American Depositary Shares

ONC

Analysis
Revolution Medicines, Inc. Common Stock

Revolution Medicines, Inc. Common Stock

RVMD

Analysis

BobbyInvestment Opinion: Should I buy INSM Today?

Rating: Buy (speculative growth). The thesis is that Insmed has crossed from a single-asset rare-disease story into a multi-product respiratory platform, with Q3 2026 revenue of $524.43 million up roughly 71% sequentially from $305.96 million in Q1 2026 and gross margin at 85.09%, while 23 of 24 analysts rate the shares Buy and the $194.18 average target implies about +60% upside from $121.16. The core reasoning is that the market is pricing a launch-stage biotech on trailing metrics (61.31x sales) while the forward framework (184.12x forward PE on consensus 2027 EPS of $10.00) is what actually matters, and the Street's $158 low target still sits 30% above the current price.

Supporting evidence: (1) valuation — PS has compressed from a 213.92x peak in Q3 2025 to 61.31x today even as revenue exploded, placing it near the low end of its multi-year band, with EV/Sales at 17.22x; (2) growth — quarterly revenue has grown more than 5.6x in six quarters, from $92.82 million in Q1 2025 to $524.43 million in Q3 2026, against a consensus revenue estimate of $6.24 billion; (3) profitability trend — Q3 2026 net loss of -$100.32 million narrowed 73% from -$370.02 million a year earlier, and Q2 2026 printed positive EBITDA of $14.16 million with a net loss of only -$13.24 million; (4) cash flow — free cash flow TTM is still -$657.58 million, but Q3 2026 FCF of -$42.09 million is a fraction of the quarterly burn a year ago, and the current ratio of 3.83x plus debt-to-equity of 1.04x mean the balance sheet is not stressed. The implied +60% upside to the average target is the anchor, and the 54% spread between the $158 low and $243 high reflects uncertainty about the ramp, not about the business.

Risks and conditions: the three biggest threats are (a) a flattening Brinsupri curve that would leave the 61.31x sales multiple without support, (b) continued cash consumption requiring equity issuance — $280.06 million was raised in Q2 2026 and cash fell $148.20 million net to $396.56 million — and (c) operating expense of $535.58 million in Q3 still outrunning $446.21 million of gross profit, producing a -17.04% operating margin. This Buy would upgrade in conviction if Q4 2026 revenue confirms sequential growth above $524.43 million and operating margin turns positive, and it would downgrade to Hold if quarterly revenue stalls or if a discounted equity raise occurs below $110; a break below the $90.39 52-week low would argue for Sell. Verdict: the stock is expensive on trailing metrics but fairly valued to modestly undervalued relative to its own forward earnings power and its compressed historical PS band — the multiple is a bet on execution, not a discount to fair value.

Sign up to view all

INSM 12-Month Price Forecast

The forward view is constructive because the fundamental inflection is already visible in the numbers — revenue scaling 5.6x in six quarters, gross margin at 85.09%, and a 73% narrowing of the quarterly loss — while the valuation has already de-rated from a 213.92x PS peak to 61.31x, meaning the market is no longer pricing perfection. The 184.12x forward PE is the crux: it is only defensible if 2027 EPS of $10.00 materializes, which requires the Brinsupri ramp to hold and the $535.58 million quarterly expense base to be absorbed rather than expanded. Analyst sentiment is a tailwind rather than a signal — 23 Buys with a $158 floor target suggests the Street sees the 36.55% one-year decline as dislocation, and the 23.90% one-month rally versus a -2.26% SPY move shows the market beginning to agree. I would upgrade to high confidence if Q4 2026 revenue exceeds $524.43 million with positive operating income, and downgrade to neutral if sequential growth stalls or a discounted raise occurs below $110.

Historical Price
Current Price $122.88
Average Target $176.00
High Target $243.00
Low Target $90.00

Wall Street consensus

Most Wall Street analysts maintain a constructive view on Insmed, Inc.'s 12-month outlook, with a consensus price target around $194.18 and implied upside of +58.0% versus the current price.

Average Target

$194.18

24 analysts

Implied Upside

+58.0%

vs. current price

Analyst Count

24

covering this stock

Price Range

$158 - $243

Analyst target range

Buy
23 (96%)
Hold
1 (4%)
Sell
0 (0%)

Coverage is deep and overwhelmingly bullish: 22-24 analysts rate the stock, with 23 Buy, 1 Hold and 0 Sell, producing a consensus recommendation of "strong_buy" and a recommendation mean of 1.29 (where 1.0 is a strong buy). The average target price of $194.18 implies approximately +60% upside from the current $121.16, a spread that signals the Street views the recent selloff as a dislocation rather than a fundamental break; the consensus leans decisively bullish, and the lone Hold is an outlier against a wall of Buy-rated coverage from Guggenheim, Morgan Stanley, Barclays, JPMorgan, Truist and Wells Fargo. The target range of $158.00 to $243.00 is wide — a 54% spread between low and high — reflecting genuine uncertainty about the brensocatib ramp and margin trajectory rather than disagreement about the business. The high target of $243.00 (roughly 2x the current price) assumes full launch execution, Arikayce label expansion contribution and multiple expansion toward the forward-earnings framework, while the low target of $158.00 still implies +30% upside and likely prices in slower uptake and continued cash burn without a downside case below the current price. Institutional ratings show stability rather than momentum — repeated Buy/Overweight reiterations from Guggenheim (Nov 2), Morgan Stanley (Oct 21), HC Wainwright and Barclays — with the only notable negative action being Wolfe Research's downgrade to Peer Perform from Outperform on October 12, a signal worth monitoring but insufficient to offset the bullish consensus.

Drowning in data?

Find the real signal!

Bulls vs Bears: INSM Investment Factors

The bull case currently has stronger evidence: revenue has grown more than 5.6x in six quarters, gross margin has expanded to 85.09%, net losses narrowed 73% year-over-year, and 23 of 24 analysts rate the stock Buy with an average target implying +60% upside. The bear case rests less on fundamentals than on price — 61.31x sales and 184x forward earnings leave no room for a launch stumble, and -$657.58 million of trailing free cash flow means the company still depends on execution, not self-funding. The single most important tension is the durability of the Brinsupri ramp: if Q4 and 2027 revenue confirm the sequential acceleration, the forward-earnings framework validates the multiple and the stock re-rates toward the $194 average target; if the curve flattens, the extreme sales multiple has nothing to stand on and the $90.39 low comes back into play. The recent 23.90% one-month rally versus a -2.26% SPY move suggests the market is already beginning to price the bull resolution.

Bullish

  • Revenue inflecting violently upward: Q3 2026 revenue hit $524.43 million, up from $305.96 million in Q1 and $425.49 million in Q2 — roughly a 71% sequential increase in two quarters. Quarterly revenue has grown more than 5.6x from $92.82 million in Q1 2025, reflecting the Brinsupri launch ramp rather than a one-off.
  • Losses narrowing sharply, margins expanding: Q3 2026 net loss of -$100.32 million compares with -$370.02 million a year earlier, a 73% narrowing, while gross margin expanded to 85.09% from 79.37%. Q2 2026 even printed positive EBITDA of $14.16 million and a net loss of only -$13.24 million, proving the business can approach breakeven at current scale.
  • Street consensus overwhelmingly bullish: 23 of 24 analysts rate the stock Buy with zero Sells, producing a recommendation mean of 1.29 (strong buy). The $194.18 average target implies roughly +60% upside from $121.16, and even the low target of $158.00 implies +30%, meaning no analyst models a downside case below the current price.
  • Valuation reset largely complete: The PS ratio has compressed from a peak of 213.92x in Q3 2025 to 61.31x today even as revenue exploded, placing it near the low end of its multi-year 35x-57x-plus band. Further upside now depends on earnings delivery rather than multiple expansion, which lowers the bar for positive surprises.

Bearish

  • Extreme valuation on every trailing metric: The stock trades at 61.31x sales and 17.22x EV/Sales — extreme even for commercial-stage biotech, where high-growth names typically trade in the single-digit to low-double-digit EV/Sales range. The 184.12x forward PE requires consensus 2027 EPS of $10.00 to materialize from a trailing loss of -$0.03.
  • Heavy cash burn and thin liquidity buffer: Free cash flow TTM is -$657.58 million, with Q3 2026 operating cash flow of -$36.46 million and FCF of -$42.09 million. Cash stood at $396.56 million after a $148.20 million net decline, and the company has relied on $280.06 million of stock issuance in Q2 2026 — dilution risk remains live.
  • Operating expense still outrunning gross profit: Q3 2026 R&D of $269.96 million plus SG&A of $253.03 million consumed $535.58 million against $446.21 million of gross profit, producing operating income of -$89.37 million (operating margin -17.04%). The loss is deliberate investment, but the gap must close for the forward PE to be validated.
  • Broken long-term trend, severe drawdown: The stock is down 36.55% over the past year and 31.59% YTD, sitting about 43% below its $212.75 52-week high and only ~25% up the 52-week range. The -56.54% maximum drawdown confirms a severe de-rating, and the 1-year relative strength of -48.82 percentage points versus SPY shows it has not reclaimed trend leadership.

INSM Technical Analysis

Insmed is in a recovery phase within a longer-term downtrend: the stock is down 36.55% over the past year and 31.59% year-to-date, yet the current price of $121.16 sits roughly 27% above the 52-week low of $90.39 and about 43% below the 52-week high of $212.75 — placing it at approximately 25% of its 52-week range (i.e., in the lower quartile). That positioning is characteristic of a broken long-term trend attempting to base, with the maximum drawdown of -56.54% confirming the severity of the prior de-rating; the stock is no longer a falling knife, but it has not reclaimed trend leadership either. The 52-week high of $212.75 now represents a distant resistance ceiling, while the $90.39 low is the line in the sand for the recovery thesis. Short-term momentum has turned decisively positive and is diverging sharply from the annual trend: the stock is up 23.90% over the past month versus a 2.26% decline in SPY, producing a relative strength of +26.16 percentage points, and it is up 11.01% over six months (relative strength +8.88). The three-month change of -2.09% is roughly in line with SPY's -2.83%, indicating the recent surge is a fresh inflection rather than a continuation — the October 29 earnings-related gap from $96.98 to $111.59 (+15%) and the subsequent grind to $121.16 mark a clear regime shift, with the 1-month/1-year divergence consistent with mean reversion off an oversold base rather than a confirmed new uptrend. Key levels are well defined: support clusters at the $90.39 52-week low, with intermediate support near the $93-$97 October consolidation zone, while resistance sits at the $132-$135 August swing high and then the $212.75 annual peak. A breakout above $135 would validate the double-bottom recovery and open a path toward the $150s, whereas a breakdown below $90 would signal fundamental deterioration and likely trigger momentum selling; with a beta of 0.808, the stock is roughly 19% less volatile than the market on a beta basis, though its realized drawdown of -56.54% and short ratio of 3.83 days-to-cover indicate event-driven gap risk that position sizing must account for.

Beta

0.81

0.81x market volatility

Max Drawdown

-56.5%

Largest decline past year

52-Week Range

$90-$213

Price range past year

Annual Return

-36.4%

Cumulative gain past year

PeriodINSM ReturnS&P 500
1m+27.6%-3.0%
3m-4.3%-3.6%
6m+13.9%-0.2%
1y-36.4%+10.1%
ytd-30.6%+8.5%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

INSM Fundamental Analysis

Revenue is inflecting violently upward: Q3 2026 revenue reached $524.43 million, up 2.68% year-over-year versus a Q3 2025 base of $142.34 million — but the more telling comparison is sequential, with revenue rising from $305.96 million in Q1 2026 to $425.49 million in Q2 and $524.43 million in Q3, a roughly 71% increase in two quarters that reflects the Brinsupri launch ramp. The multi-quarter trend shows acceleration, not deceleration: quarterly revenue has grown from $92.82 million in Q1 2025 to $524.43 million in Q3 2026, more than 5.6x in six quarters, and the single reportable segment figure of $406.19 million underscores that the respiratory franchise is the entire growth engine. Consensus modeled revenue of approximately $6.24 billion (average estimate, range $5.55-$6.97 billion) implies the market expects this trajectory to continue, making the durability of the launch the central variable for the investment case. Profitability is improving rapidly but remains negative: Q3 2026 net income was -$100.32 million (EPS -$0.46) versus -$370.02 million in Q3 2025, a 73% narrowing of the loss, while gross margin expanded to 85.09% from 79.37% a year earlier and 84.20% in Q2 2026. The loss is now driven by deliberate investment rather than structural unprofitability — R&D of $269.96 million and SG&A of $253.03 million in Q3 consumed $535.58 million of operating expense against $446.21 million of gross profit, producing operating income of -$89.37 million (operating margin -17.04%) and EBITDA of -$68.85 million. The trajectory is encouraging: Q2 2026 EBITDA was positive at $14.16 million and net income was only -$13.24 million, showing the business can approach breakeven at current scale, and the 85% gross margin is consistent with premium orphan-drug economics. Balance-sheet risk is manageable but not trivial: free cash flow TTM is -$657.58 million, Q3 2026 operating cash flow was -$36.46 million with capex of -$5.63 million (FCF -$42.09 million), and cash stood at $396.56 million at quarter-end after a $148.20 million net cash decline. Debt-to-equity is 1.04x, the current ratio is a healthy 3.83x, and ROE of -172.78% and ROA of -17.25% reflect the still-negative earnings base rather than solvency stress; the company funded itself partly through $24.48 million of stock issuance in Q3 and $280.06 million in Q2, so continued execution on the launch — not external financing — is what closes the FCF gap.

Quarterly Revenue

$524428000.0B

2026-09

Revenue YoY Growth

+268.4%

YoY Comparison

Gross Margin

85.1%

Latest Quarter

Free Cash Flow

$-657575000.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Reportable Segment

Open an Account, get $2 TSLA now!

Valuation Analysis: Is INSM Overvalued?

Because trailing net income is negative (EPS -$0.03, trailing PE -27.15x), the PE ratio is not meaningful and I lead with the price-to-sales ratio of 61.31x, supplemented by EV/Sales of 17.22x; the forward PE of 184.12x is the more informative multiple, since it implies the market expects a dramatic swing to profitability — consensus 2027 EPS of $10.00 (range $8.56-$11.52) versus a trailing loss. The gap between the negative trailing PE and the 184x forward PE is the entire valuation story: investors are paying today for earnings that do not yet exist, and the forward multiple only compresses to a still-rich level if the modeled $6.24 billion revenue base and margin expansion materialize. On a peer basis, the 61.31x PS and 17.22x EV/Sales are extreme even for biotechnology, where high-growth commercial-stage names typically trade in the single-digit to low-double-digit EV/Sales range; the premium is justified only by the 5.6x six-quarter revenue ramp and 85% gross margin, and the 50.31x price-to-book (versus a book value depressed by accumulated losses) offers little valuation support. The stock is expensive on every trailing metric but cheap relative to its own forward earnings power — a classic launch-stage biotech profile where the multiple is a bet on execution rather than a discount to fair value. Historically, Insmed's PS ratio has ranged from roughly 35x-57x in 2021-2023 to a peak of 213.92x in Q3 2025 and 140.92x at year-end 2025, before compressing to 61.31x today; the current level is near the low end of its multi-year band, suggesting the market has already de-rated the stock substantially and is no longer pricing in perfection. That compression — from 213.92x to 61.31x PS even as revenue exploded — means the valuation reset is largely complete, and further upside now depends on earnings delivery rather than multiple expansion.

PE

-27.2x

Latest Quarter

vs. Historical

N/A

5-Year PE Range 17x~59x

vs. Industry Avg

29.3x

Industry PE ~29.3x*

EV/EBITDA

-32.0x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on cash consumption and the dependence on continued growth to justify valuation. Free cash flow TTM is -$657.58 million, Q3 2026 operating cash flow was -$36.46 million, and cash fell $148.20 million net to $396.56 million — a buffer that covers roughly two to three quarters of the current burn without new financing. The company has already tapped equity markets for $280.06 million in Q2 2026 and $24.48 million in Q3, so further dilution is a live risk if the launch ramp slows. Operationally, the franchise is concentrated: a single reportable segment generated $406.19 million, and the respiratory business (Arikayce plus Brinsupri) is effectively the entire growth engine, so any label, reimbursement, or uptake setback hits the whole thesis. Debt-to-equity of 1.04x and a current ratio of 3.83x indicate the balance sheet is not stressed today, but ROE of -172.78% and ROA of -17.25% show how thin the equity base is relative to accumulated losses.

Market and competitive risks are dominated by valuation compression and event-driven volatility. At 61.31x sales and 17.22x EV/Sales, the stock carries a premium that assumes flawless launch execution; a peer de-rating or a single quarter of slower Brinsupri uptake could compress the multiple sharply, as the fall from a 213.92x PS peak already demonstrated. Competition is intensifying in pulmonary arterial hypertension and orphan lung disease — recent coverage explicitly names Insmed alongside United Therapeutics as a competitive constraint on Liquidia's Yutrepia — and any share loss in adjacent respiratory categories would undermine the platform narrative. The beta of 0.808 suggests roughly 19% less market sensitivity than the average stock, but the short ratio of 3.83 days-to-cover and the -56.54% realized drawdown show that idiosyncratic, news-driven gap risk dominates macro correlation for this name. Wolfe Research's October 12 downgrade to Peer Perform is an early signal that some sell-side patience with the ramp is finite.

A worst-case scenario would combine a flattening Brinsupri curve with a delayed or narrowed Arikayce label expansion and a financing event at a depressed price. In that chain, revenue growth decelerates below the consensus $6.24 billion trajectory, the 184x forward PE loses its earnings anchor, and the stock retests its 52-week low of $90.39 — roughly -25% from the current $121.16. A more severe outcome, consistent with the -56.54% maximum drawdown already experienced, would take the shares toward the mid-$50s to $60s if the launch stalls and the company raises equity at a discount. Note that even the lowest analyst target of $158.00 sits above the current price, so the quantified sell-side downside is limited; the real downside risk is the historical drawdown pattern, not the published targets. Position sizing should assume a realistic -25% to -40% adverse range from $121.16.

FAQ

Ranked by severity: first, launch durability — the entire thesis rests on the Brinsupri ramp, and a flattening curve would leave 61.31x sales unsupported, with the $158-$243 target spread (a 54% gap) showing analysts genuinely disagree on uptake. Second, financing — trailing free cash flow is -$657.58 million, cash fell $148.20 million net to $396.56 million, and $280.06 million of stock was issued in Q2 2026, so a discounted raise is a live dilution risk. Third, valuation compression — the fall from a 213.92x PS peak to 61.31x shows how fast the multiple can contract, and Wolfe Research's October 12 downgrade to Peer Perform signals finite sell-side patience. Fourth, competitive and event risk — Insmed is named alongside United Therapeutics as a constraint on Liquidia's Yutrepia in PAH, and the 3.83-day short ratio plus -56.54% maximum drawdown confirm news-driven gap risk.

The base case carries 50% probability with a $158-$194 range, assuming the launch continues at a moderating sequential pace, gross margin holds near 85.09%, and the stock grinds toward the $194.18 average target. The bull case at 30% probability targets $194-$243, requiring Q4 2026 revenue above $524.43 million, a positive operating margin, and the Arikayce label expansion converting into revenue. The bear case at 20% probability targets $90-$158, driven by a flattening Brinsupri curve, a discounted equity raise, or an FDA setback, with the $90.39 52-week low as the floor. The most likely outcome is the base case, and its key assumption is that sequential revenue growth stays positive each quarter while expenses remain in the $500-550 million range.

The verdict depends on the lens. On trailing metrics it is expensive: 61.31x price-to-sales, 17.22x EV/Sales, and 50.31x price-to-book, with a negative trailing PE of -27.15x because EPS is -$0.03. On forward earnings the picture changes — the 184.12x forward PE is high in absolute terms but reflects the market pricing a swing to consensus 2027 EPS of $10.00 (range $8.56-$11.52) from a trailing loss, and that multiple compresses quickly if the $6.24 billion consensus revenue base materializes. Relative to its own history the stock is cheap: PS has fallen from a 213.92x peak in Q3 2025 to 61.31x today even as revenue scaled, placing it near the low end of its multi-year band. The market is therefore paying a premium to biotech peers but a steep discount to Insmed's own past, implying it now expects execution rather than perfection.

The risk/reward is favorable but not low-risk: at $121.16 the $194.18 average analyst target implies about +60% upside, and even the lowest published target of $158.00 sits roughly 30% above spot, meaning no covering analyst models downside from here. The fundamental case is concrete — Q3 2026 revenue of $524.43 million versus $92.82 million in Q1 2025, gross margin of 85.09%, and a quarterly net loss that narrowed 73% year-over-year to -$100.32 million. The offset is valuation and cash: 61.31x sales and 184.12x forward earnings leave no margin for a launch stumble, and -$657.58 million of trailing free cash flow keeps dilution on the table. The biggest downside risk is a retest of the $90.39 52-week low, roughly -25% from the current price. It is a good buy for growth-oriented investors with an 18-24 month horizon who can tolerate that drawdown, and a poor fit for capital-preservation or income mandates given the 0% dividend yield.

This is primarily a long-term holding, with a suggested minimum horizon of 18-24 months to span the Brinsupri launch curve and the 2027 earnings inflection that the 184.12x forward PE depends on. The company pays no dividend (payout ratio 0%) and has negative trailing EPS of -$0.03, so there is no income component and no yield support during drawdowns. Volatility argues against short-term trading: beta is 0.808, but the -56.54% maximum drawdown, 3.83-day short ratio, and the October 29 gap from $96.98 to $111.59 (+15%) show event-driven moves that can overwhelm risk controls. Earnings visibility is improving but still limited — the 54% spread between the $158 and $243 targets is the clearest measure of how uncertain the next several quarters remain.